MedTrace Logo

Study in High Risk Patients Switched From Higher Doses of Other Statins to Crestor on the Percentage of Patients Reaching the New LDL-C Target Goal

NCT00240344 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2650

Last updated 2011-08-30

No results posted yet for this study

Summary

The purpose of this study is to determine the efficacy of Crestor in high risk patients switched from higher doses of other statins in obtaining the new European Atherosclerosis Society (EAS) low-density lipoprotein cholesterol (LDL-C) guidelines.

Conditions

Sponsors & Collaborators

Principal Investigators

  • AstraZeneca Netherlands Medical Director, MD · AstraZeneca

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-09-30
Primary Completion
2008-02-29
Completion
2008-02-29

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00240344 on ClinicalTrials.gov